1. Introduction {#sec1}
===============

Mesenchymal stromal/stem cells (MSCs) are multipotent cells characterized by their ability to differentiate into adipocytes, chondrocytes, and osteoblasts, their expression of surface markers CD73, CD90, and CD105, and their lack of hematopoietic lineage markers \[[@B1]--[@B4]\]. MSCs were initially studied for their ability to support hematopoietic stem cells in the bone marrow, but now they are being studied for their regenerative and immunomodulatory properties, as they home to injured tissues and contribute to tissue repair and suppression of inflammatory damage \[[@B5], [@B6]\]. MSCs have been isolated from a number of different tissues, including bone marrow, adipose, heart, vocal cord, and pancreatic islets \[[@B7]--[@B10]\]. They are also present in the tumor microenvironment, where they support the growth of tumor cells, activate mitogen and stress signaling, and increase resistance to cytotoxins \[[@B11]--[@B13]\].

MSCs have immunomodulatory properties and suppress the proliferation of CD4^+^ T cells, CD8^+^ T cells, B cells, and NK cells, while they induce the proliferation of regulatory T cells (Tregs) \[[@B5], [@B6], [@B14]--[@B21]\]. In addition, MSCs alternatively activate macrophages and bias them toward an immunosuppressive M2 phenotype \[[@B22]\]. Further evidence of MSCs creating a more anti-inflammatory state includes the following actions: induction of type 1 dendritic cells to reduce TNF*α* secretion and type 2 dendritic cells to increase IL-10 secretion \[[@B16], [@B23], [@B24]\]; causing Th1 cells to decrease IFN*γ* secretion and Th2 cells to increase IL-4 secretion \[[@B16]\]; decreasing NK cell proliferation and IFN*γ* secretion \[[@B14]\]; and converting macrophages to an anti-inflammatory immunophenotype \[[@B22]\]. At the same time, MSCs express low levels of MHC class I and no MHC class 2 and costimulatory molecules CD40, CD80, and CD86, preventing alloreactive antibody production and destruction \[[@B25], [@B26]\]. Due to these multimodal properties, MSCs are being studied for their potential use in different modes of therapy: (1) produce new tissues (e.g., cartilage repair); (2) assist with healing tissue damage (e.g., cardiovascular disease); (3) improve engraftment of other cells and tissues (e.g., hematopoietic cells and pancreatic islets); and (4) treat immune based pathologies (e.g., graft versus host disease, GVHD) \[[@B27]--[@B37]\].

MSCs have also been extensively studied because of their ability to differentiate into adipocytes, chondrocytes, and osteoblasts, which has significant potential in the field of regenerative medicine. However, MSCs are much farther from reaching clinical utility in regenerative medicine as compared to their utility in immunomodulation. Their chondrogenic ability has arguably gained the most attention \[[@B38]\] and could be utilized to aid in reconstitution of connective tissue loss in many joints, namely, the knee, which is crucial given the fact that chondrocytes are terminally differentiated, quiescent cells and do not regenerate damaged tissue.

While MSCs have been utilized with some success in the clinic, there is room for improvement in order for them to reach their full clinical potential. First, MSCs are rare cells*in situ* and must be expanded*ex vivo* in order to be utilized in the clinic. However, MSCs undergo replicative senescence, limiting the number of divisions \[[@B39]--[@B41]\]. Furthermore, this replicative senescence also compromises their immunomodulatory and differentiation functions and possibly their clinical activity against GVHD and other inflammatory pathologies \[[@B42], [@B43]\]. In addition, there is a lack of a well-defined and accepted potency assay to functionally assess MSC products \[[@B37], [@B44]\].

Another problem is the loss of transplanted MSCs at the site of graft, particularly after*ex vivo* culture \[[@B45], [@B46]\], which could possibly be due to loss of chemokine receptors \[[@B47]\]. Reactive oxygen species (ROS) and nonspecific inflammation generated at the ischemic site of injury have been hypothesized to lead to loss of transplanted MSCs from this site \[[@B48]--[@B50]\]. Therefore, there is great need to identify methods to manipulate MSCs to reduce ROS in both the MSCs themselves during their culture expansion production phase and in the injured tissue microenvironment in order to promote MSC engraftment and enhance tissue repair. First, this requires an understanding of the contributions of oxidative stress to MSC biology.

2. Oxidative Stress and MSC Differentiation {#sec2}
===========================================

Oxidative stress is characterized by deregulated production and/or scavenging of reactive oxygen and nitrogen species (ROS and RNS, resp.). ROS are primarily generated from mitochondrial complexes I and III and NADPH oxidase isoform NOX4 during MSC differentiation \[[@B51]\]. The accumulation of free radicals can damage essentially all biomolecules, including DNA, protein, and lipids. High ROS levels cause cellular damage and dysfunction, but it is thought that a low basal level of ROS is necessary and advantageous in order to maintain cellular proliferation, differentiation, and survival \[[@B52]--[@B54]\]. Indeed, at baseline, MSCs have low levels of ROS and high levels of glutathione, the major cellular antioxidant \[[@B55]\]; however, other reports suggest that MSCs have low antioxidant activity and are more sensitive to oxidative stress compared to more differentiated cell types \[[@B56], [@B57]\]. In MSCs, excess ROS or exogenous addition of H~2~O~2~ can impair self-renewal, differentiation capacity, and proliferation \[[@B57]--[@B61]\]; concordantly, antioxidants stimulate MSC proliferation \[[@B62]\].

With regard to osteogenic differentiation, most studies suggest that ROS inhibit osteogenic differentiation \[[@B63]\]. Furthermore, addition of exogenous H~2~O~2~ reduces osteogenic differentiation in human and murine MSCs and osteoblast precursors \[[@B63]--[@B65]\]. In addition, MSCs from older donors demonstrate decreased osteogenic potential \[[@B66]\].*In vitro* induction of osteogenesis in human MSCs is associated with an upregulation of mtDNA copy number, protein subunits of respiratory enzymes, superoxide dismutase 2 (SOD2, alias MnSOD), catalase oxygen consumption rate, and antioxidant enzymes, but a decrease in ROS \[[@B63]\]; undifferentiated MSCs showed higher levels of glycolytic enzymes and a higher lactate production rate, suggesting that MSCs rely more on glycolysis for energy supply in comparison with MSC-differentiated osteoblasts, which rely more on oxidative mitochondrial metabolism. These findings support the idea that ROS and oxidative stress must decrease to allow for osteogenic differentiation to proceed. However, it appears that at least a basal level of ROS may be required, as some reports show that ROS enhance calcification and osteogenesis \[[@B67]\]; one caveat is that this study investigated murine vascular smooth muscle cells, which could explain the difference. In summary, ROS and aging inhibit MSC osteogenesis.

With regard to adipogenesis, ROS increase as MSCs differentiate into adipocytes, but it is unclear whether this is a cause or consequence of adipogenesis. Antioxidant enzymes such as SOD, catalase, and GPX are upregulated during adipogenesis in human MSCs \[[@B68]\]. It has been reported that ROS and the addition of exogenous H~2~O~2~ induce adipogenesis in human and murine MSCs and adipocyte precursors \[[@B51], [@B68], [@B69]\], lending credence for the idea that ROS play a causal role in adipogenesis. Furthermore, this effect of H~2~O~2~ is dose-dependent, as higher doses of H~2~O~2~ increased adipogenesis \[[@B70]\]. Consistent with ROS stimulating adipogenesis, the ROS scavenger*N*-acetylcysteine (NAC) inhibited adipogenesis in the mouse MSC cell line 10T1/2 \[[@B71]\]. In addition, it has been demonstrated that ROS generated by mitochondrial complex III are imperative for the activation of adipogenic transcription factors \[[@B72]\]. Similar to osteogenic differentiation, mitochondrial biogenesis and oxygen consumption increase significantly during adipogenesis \[[@B73], [@B74]\]. Additionally, inhibiting mitochondrial respiration significantly suppresses adipogenic differentiation \[[@B73]\], which makes sense for two reasons: (1) mitochondrial biogenesis and metabolism are thought to be important for MSC differentiation \[[@B74]\] and (2) inhibiting mitochondrial metabolism reduces ROS, and ROS are thought to stimulate adipogenesis. There is an increase in SOD3 expression with the differentiation of human MSCs into adipocytes \[[@B75]\] and during the early stages of adipogenic differentiation in 3T3-L1 cells \[[@B54]\]. However, there are some reports that contradict the idea that ROS stimulate adipogenesis; these reports demonstrate that aging and senescence, which are often associated with higher oxidative stress, decrease adipogenic differentiation \[[@B41], [@B76]--[@B78]\]. Additionally, RNAi-mediated depletion of MnSOD, which results in higher ROS, reduces the expression of late adipogenesis markers such as adiponectin and fatty acid-binding protein 4 (FABP4) \[[@B79]\]. Nevertheless, the prevailing view is that ROS and aging enhance adipogenesis \[[@B54]\].

ROS generally increase during chondrogenesis, and ROS generated by NADPH oxidases 2 and 4 are necessary for chondrogenic differentiation of murine primary chondrocytes and the ATDC5 cell line \[[@B80]\]. Consistent with this, SOD3 levels were reduced upon chondrogenesis \[[@B75]\]; SOD3 is known to help reduce ROS in the extracellular matrix. Furthermore, ROS scavenging with NAC blocked chondrogenic differentiation \[[@B80]\]. Consistent with this, increasing ROS levels stimulated chondrocyte hypertrophy, and this effect was inhibited by NAC \[[@B81]\].

3. Oxidative Stress and MSC Immunomodulation {#sec3}
============================================

Evidence of the direct role of oxidative stress in MSC immunomodulation is lacking. However, we do know that as MSCs are expanded*ex vivo*, proliferation decreases, oxidative stress increases, the level of certain surface antigens decreases (e.g., CD13, CD29, and CD44), and the ability to suppress T cell proliferation diminishes \[[@B41], [@B82], [@B83]\]. Similarly, MSCs from older donors, which also likely have greater oxidative stress, have reduced capacity to inhibit T cell proliferation \[[@B84], [@B85]\]. In addition, MSCs from human patients with atherosclerosis and type 2 diabetes, two diseases associated with elevated oxidative stress, have reduced ability to inhibit T cell proliferation \[[@B85]\]. However, some studies conflict with the assertion that donor age negatively impacts MSC suppression of T cell proliferation \[[@B86], [@B87]\]; one of these studies analyzed 53 human donors ranging within 13--80 years demonstrated no significant correlation between age and T cell suppression capability \[[@B86]\].

As most of the clinical uses of MSCs are dependent on their immunomodulatory properties, it will be important to continue to elucidate how oxidative stress affects MSC immunomodulation and whether or not modulating ROS and oxidative stress can enhance MSC*ex vivo* expansion, immunomodulation, and clinical utility.

4. Sirtuins, Oxidative Stress, and*Ex Vivo* Expansion of MSCs {#sec4}
=============================================================

Oxidative stress also affects*ex vivo* culture expansion and longevity of MSCs, which has implications for cell therapy. As MSCs are continuously passaged and grown*ex vivo*, they undergo replicative senescence, and proliferation decreases \[[@B39]--[@B42], [@B88], [@B89]\]. Aging and senescence are associated with greater oxidative stress, which limit the number of times that MSCs can be passaged and the quality of the cells \[[@B90], [@B91]\]. Therefore, there is great need to identify methods to prevent oxidative stress and replicative senescence in MSCs.

One potential method to reduce oxidative stress in MSCs is by modulating sirtuin expression and/or activity. Sirtuins are protein deacetylases that are thought to play evolutionarily conserved roles in lifespan extension \[[@B92]--[@B94]\]. Humans have seven sirtuins (SIRT1--7) that localize to distinct subcellular compartments and serve very distinct functions \[[@B95], [@B96]\]. In general, sirtuins are protective against age-related pathologies such as hearing loss \[[@B97]\], neurodegeneration \[[@B98]\], metabolic disease \[[@B99], [@B100]\], and cancer \[[@B101], [@B102]\]. Their roles in MSCs have not been fully elucidated and represent an interesting avenue of future research.

SIRT1, SIRT6, and SIRT7 localize to the nucleus. SIRT1 deacetylates a number of protein substrates including p53, DNA methyltransferase 1 (DNMT1), NF-*κ*B, forkhead transcription factors, PGC-1*α*, and histones \[[@B103]--[@B108]\]; an unbiased mass spectrometry-based acetylome analysis has revealed many more potential substrates \[[@B109]\]. SIRT1 knockdown decreases MSC proliferation and differentiation and increases senescence, and the opposite occurs with SIRT1 overexpression \[[@B110]\]. Consistently, SIRT1 activation with resveratrol enhances MSC osteogenesis \[[@B111]\]. SIRT1 is downregulated during human embryonic stem cell (ESC) differentiation at both mRNA and protein levels \[[@B112]\]. Therefore, SIRT1 is crucial for stem cell maintenance and differentiation. SIRT6 deacetylates histones H3K9Ac and H3K56Ac \[[@B113], [@B114]\] and is an imperative regulator of metabolism, transcription, telomere maintenance, and DNA repair in response to oxidative stress \[[@B115], [@B116]\]. It ADP-ribosylates and thereby activates PARP1, allowing for efficient double-strand break repair in the face of oxidative stress \[[@B116]\]. Furthermore, SIRT6 rescues the decline of base excision repair and homologous recombination repair during replicative senescence in primary human fibroblast strains \[[@B117], [@B118]\]. A study of human dermal fibroblasts from older subjects demonstrated that reprogramming into induced pluripotent stem cells (iPSCs) with Yamanaka factors was less efficient than in fibroblasts from older subjects, but that adding SIRT6 improved the efficiency of reprogramming \[[@B119]\]. Specific to MSCs, knockdown of SIRT6 inhibited while overexpression enhanced osteogenesis in rat MSCs \[[@B120]\]. Recent studies have demonstrated the possibility of activating SIRT6 with long-chain fatty acids \[[@B121]\], which may represent a way to modulate MSC function and longevity. The final nuclear sirtuin, SIRT7, has been less well characterized but localizes to the nucleolus and regulates rDNA transcription \[[@B122]\]. This is dependent on the deacetylation of U3-55k, a component of the U3 snoRNP complex, and this deacetylation enhances rRNA transcription and processing \[[@B123]\]. It is also important for proliferation and inhibition of apoptosis \[[@B122]\], perhaps via deacetylation of p53 \[[@B124]\]. In addition, SIRT7 has been recently shown to promote the regenerate capacity of aged hematopoietic stem cells, as inactivation increased mitochondrial protein folding stress and reduced regenerative capacity \[[@B125]\].

SIRT3, SIRT4, and SIRT5 localize to the mitochondria, where approximately 90% of ROS are produced in mitochondria \[[@B126]\]. SIRT3 is the major mitochondrial deacetylase and reprograms mitochondrial metabolism away from carbohydrate metabolism in favor of more efficient electron transport, which is thought to result in reduced ROS production \[[@B127]--[@B130]\]. SIRT3 deacetylates and thereby activates isocitrate dehydrogenase 2 (IDH2), an enzyme that catalyzes the TCA cycle redox conversion of isocitrate to *α*-ketoglutarate and serves as a major source of NADPH production \[[@B97], [@B131], [@B132]\]. SIRT3 also deacetylates and thereby activates superoxide dismutase 2 (SOD2, alias MnSOD), which also neutralizes ROS \[[@B133]--[@B135]\]. One of the only studies of SIRT3 on stem cell function demonstrated that SIRT3 is not required for hematopoietic stem cell (HSC) maintenance and tissue homeostasis at a young age in mice; however, SIRT3 is imperative in HSCs at an older age and under stress \[[@B136]\]. Importantly, SIRT3 expression decreases with aging, and this is accompanied by a concomitant decrease in SOD2 activity; overexpressing SIRT3 in these aged HSCs reduces oxidative stress and improves their regenerative capacity \[[@B136]\]. SIRT3 overexpression can also protect against low-oxygen and low-glucose stresses \[[@B137]\]. Similarly, SOD2 acetylation, a target of SIRT3 deacetylation, increases with age in rats and humans, which can be restored*in vitro* by adding recombinant SIRT3 \[[@B138]\]. The next mitochondrial sirtuin, SIRT4, mono-ADP-ribosylates and thereby inhibits glutamate dehydrogenase, which slows the conversion of glutamate to *α*-ketoglutarate \[[@B139]--[@B141]\]. SIRT4 is also a lipoamidase that hydrolyzes the lipoamide cofactors from the E2 component of the pyruvate dehydrogenase (PDH) complex, which reduces the activity of the complex \[[@B142]\]. Defects in the PDH complex have been shown to increase ROS and oxidative stress \[[@B143]\]. Similarly, SIRT4 and ROS are upregulated during replicative senescence and in response to DNA damage \[[@B144], [@B145]\]; however, one study shows that SIRT4 depletion reduces ROS \[[@B144]\] and therefore suggests that inhibiting SIRT4 may be a strategy to prevent oxidative stress in MSCs, while another believes that SIRT4 is required for appropriate recovery from cellular stresses \[[@B145]\]. Further study of SIRT4 in MSCs is warranted. The final mitochondrial sirtuin, SIRT5, is the major mitochondrial desuccinylase \[[@B146], [@B147]\]. It desuccinylates and activates SOD1 to facilitate the elimination of ROS \[[@B148]\]. SIRT5 has not been studied in stem cells, but based on these known functions, we hypothesize that SIRT5 helps maintain ROS at low levels to preserve stem cell function and longevity.

SIRT2 is a cytoplasmic sirtuin that deacetylates and therefore destabilizes *α*-tubulin \[[@B149]\]. Furthermore, SIRT2 deacetylates p300, a histone acetyltransferase crucial for many biological processes including cellular proliferation and differentiation, which increases the affinity of p300 for preinitation complexes \[[@B150]\]; in this way, SIRT2 may help control transcription of genes needed for MSC differentiation. SIRT2 gene expression increases with differentiation of mouse ESCs \[[@B151]\]. In stem cells, SIRT2 has been shown to inhibit the expression of keratin 19, which is a stem cell marker \[[@B152]\]. These two studies suggest that SIRT2 is more important for differentiation. However, it may be specific to the type of differentiation being discussed; downregulation of SIRT2 promotes 3T3L1 adipocyte differentiation \[[@B153]\], and SIRT2 knockdown in mouse ESCs promotes differentiation into mesodermal and endodermal tissues and diminishes differentiation into ectodermal tissues \[[@B151]\]. Lastly, SIRT2 may play a role in autophagy, the catabolic process that allows the cell to recycle damaged proteins and organelles and has been shown to be important for stem cell function, particularly in the face of oxidative stress \[[@B154]\]; however, more work needs to be done here, as the exact role of autophagy in MSC biology is unclear. Nevertheless, most reports suggest that SIRT2 inhibits autophagy. One report shows that depletion of SIRT2 activates autophagy \[[@B155]\]. Consistent with this, another study shows that the FoxO1 transcription factor is required for autophagy caused by oxidative stress, and that dissociation from SIRT2 increases FoxO1 acetylation and induction of autophagy \[[@B156]\]; this suggests that SIRT2 inhibits autophagy. Therefore, modulation of SIRT2 expression and activity is worth further pursuing.

5. Conclusions {#sec5}
==============

MSCs have immense therapeutic potential; yet this potential has not been reached for a number of reasons. Perhaps one of these reasons is the effect of oxidative stress on MSC*ex vivo* expansion, leading to problems with*in vivo* function and engraftment. Therefore, there is great need to identify novel methods to optimize ROS levels in MSCs to enhance their immunomodulatory and regenerative abilities so that their full therapeutic potential can be realized. The sirtuins represent a potential way to achieve this and warrant further study in MSCs. Many of the sirtuins may help enhance our ability to expand MSCs*ex vivo* for eventual clinical use.
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